Loading
Liver Biomarkers / Placebo (Starch Capsule) / Lipid Profile · Interventional Study
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed but unpublished randomized controlled trial comparing two doses of sumac supplementation plus calorie restriction versus placebo in 102 grade-I obese patients with NAFLD. No results are posted in this registry record, so the efficacy and safety of the intervention cannot be evaluated.
Interventional, Randomized, Parallel, Single masking, Health Services Research purpose. Liver Biomarkers, Lipid Profile, Glucose, Insulin; age from 30 Years; to 60 Years; accepts healthy volunteers. Intervention: T1; T2. Compared with: T0 — Placebo Comparator. n = 102. 1 site: Pakistan.
This is a completed but unpublished randomized controlled trial comparing two doses of sumac supplementation plus calorie restriction versus placebo in 102 grade-I obese patients with NAFLD. No results are posted in this registry record, so the efficacy and safety of the intervention cannot be evaluated.
No safety or adverse event data are available.
The source did not state who this applies to in practice.
This is a completed registry record with no results posted; the study design is sound (RCT, n=102) but evidence cannot be evaluated until outcomes are reported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07768657). This is a study registration, not published results. Lead sponsor: University of Lahore. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 102 participants (ACTUAL). Conditions: Liver Biomarkers, Lipid Profile, Glucose, Insulin. Interventions: DIETARY_SUPPLEMENT: T1 SUMAC SUPPLEMENT; DIETARY_SUPPLEMENT: T2 SUMAC SUPPLEMENT; DIETARY_SUPPLEMENT: Placebo (Starch Capsule). Primary outcome measures: LIVER ENZYMES , 12 WEEK; LIPID PROFILE , 12 weeks; INSULIN RESISTANCE , 12-weeks. Brief summary: This randomized controlled trial aims to evaluate the effects of Rhus coriaria L. (Sumac) supplementation combined with a calorie-restricted diet on hepatic function and metabolic health in grade-I obese patients with non-alcoholic fatty liver disease (NAFLD). A total of 102 participants aged 30-60 years with confirmed NAFLD will be randomly assigned to one of three groups: placebo, 1.5 g/day Sumac supplementation, or 3.0 g/day Sumac supplementation for 12 weeks. Outcomes will include changes in liver function tests (ALT, AST, and ALP), anthropometric measurements, glycemic control, insulin resistance, lipid profile, and inflammatory biomarkers. The study aims to determine whether Sumac supplementation provides additional benefits beyond calorie restriction alone in improving hepatic health and metabolic risk factors associated with NAFLD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.